William Blair Has Optimistic Outlook of WST Q3 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – William Blair upped their Q3 2025 earnings estimates for shares of West Pharmaceutical Services in a research report issued to clients and investors on Thursday, July 24th. William Blair analyst M. Larew now expects that the medical instruments supplier will earn $1.68 per share for the quarter, up from their prior forecast of $1.60. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. William Blair also issued estimates for West Pharmaceutical Services’ Q4 2025 earnings at $1.83 EPS, FY2025 earnings at $6.81 EPS, Q1 2026 earnings at $1.63 EPS, Q2 2026 earnings at $1.98 EPS, Q3 2026 earnings at $1.93 EPS, Q4 2026 earnings at $2.11 EPS and FY2026 earnings at $7.67 EPS.

Other equities analysts also recently issued research reports about the stock. Barclays initiated coverage on shares of West Pharmaceutical Services in a report on Tuesday, June 24th. They set an “equal weight” rating and a $245.00 price target for the company. UBS Group increased their price objective on shares of West Pharmaceutical Services from $285.00 to $320.00 and gave the company a “buy” rating in a report on Friday. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Evercore ISI raised their price objective on shares of West Pharmaceutical Services from $275.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Stephens raised shares of West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, April 21st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $320.71.

West Pharmaceutical Services Price Performance

WST opened at $263.32 on Monday. The firm has a market cap of $18.92 billion, a price-to-earnings ratio of 39.42, a price-to-earnings-growth ratio of 5.92 and a beta of 1.09. The company’s 50-day moving average price is $220.56 and its 200 day moving average price is $237.85. West Pharmaceutical Services has a fifty-two week low of $187.43 and a fifty-two week high of $352.33. The company has a quick ratio of 2.08, a current ratio of 2.78 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.33. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%. The company had revenue of $766.50 million for the quarter, compared to the consensus estimate of $725.11 million. During the same quarter last year, the business posted $1.52 EPS. West Pharmaceutical Services’s quarterly revenue was up 9.2% compared to the same quarter last year.

West Pharmaceutical Services Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 19th. Shareholders of record on Wednesday, November 12th will be paid a dividend of $0.22 per share. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 0.33%. The ex-dividend date is Wednesday, November 12th. West Pharmaceutical Services’s payout ratio is 12.57%.

Institutional Trading of West Pharmaceutical Services

Several hedge funds and other institutional investors have recently modified their holdings of the business. Zions Bancorporation National Association UT purchased a new position in West Pharmaceutical Services during the first quarter valued at approximately $25,000. Quarry LP purchased a new stake in shares of West Pharmaceutical Services during the first quarter worth $27,000. First Horizon Advisors Inc. boosted its position in West Pharmaceutical Services by 85.0% during the first quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 85 shares during the last quarter. Cromwell Holdings LLC grew its stake in West Pharmaceutical Services by 587.5% in the second quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 188 shares in the last quarter. Finally, Opal Wealth Advisors LLC acquired a new position in West Pharmaceutical Services in the 1st quarter worth about $53,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.